Sofinnova Investments, Inc. Immuno Gen, Inc. Transaction History

Sofinnova Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 15, 2024	BUY	$12.46 - $29.95 $19.3 Million - $46.3 Million	1,546,902 New	1,546,902 $45.9 Million
Q4 2023 Feb 12, 2024	BUY	$12.46 - $29.95 $8.97 Million - $21.6 Million	719,584 Added 86.98%	1,546,902 $45.9 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $364,552 - $1.95 Million	-97,214 Reduced 10.51%	827,318 $15.6 Million
Q1 2023 May 11, 2023	SELL	$3.67 - $4.92 $2.8 Million - $3.75 Million	-761,622 Reduced 45.17%	924,532 $3.55 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $5.39 Million - $7.47 Million	1,183,761 Added 235.62%	1,686,154 $8.36 Million
Q3 2022 Nov 08, 2022	SELL	$4.48 - $6.47 $2.86 Million - $4.13 Million	-638,395 Reduced 55.96%	502,393 $2.4 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $905,250 - $1.66 Million	-287,381 Reduced 20.12%	1,140,788 $5.13 Million
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $1.37 Million - $2.41 Million	-321,713 Reduced 18.38%	1,428,169 $6.8 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $6.19 Million - $9.77 Million	1,302,807 Added 291.41%	1,749,882 $13 Million
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $1.76 Million - $4.34 Million	447,075 New	447,075 $2.15 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.